Board Of Directorsabout : board of directors
Members Of The Board
 Dr. Aladar A. Szalay, who formed Genelux Corporation in 2001, is internationally recognized as a leader in the monitoring of gene regulation and in whole cell and live organism imaging using light-emitting proteins or protein fusions. Based on his long-time research interest and recent discoveries, the company is utilizing live microorganisms to locate (diagnose) and eliminate (therapy) human tumor xenografts. In addition, to guide the research and development program of Genelux Corporation, Dr. Szalay currently holds a university professor position at the Rudolf Virchow Center of Experimental Biomedicine, School of Medicine, and also at the Biocenter at the University of Würzburg in Würzburg, Germany, where he directs a research program with graduate students and post-doctoral fellows on whole body imaging. He was recently appointed to a full professor position in the Department of Radiation Oncology at the Rebecca and John Moores Comprehensive Cancer Center, at the University of California, San Diego. His previous academic appointments were: professor of molecular genetics and microbiology and founding director of the Center for Molecular Biology and Gene Therapy at Loma Linda University School of Medicine in Loma Linda, California; Canadian Pacific Endowed Chair Professor of biotechnology and molecular genetics at the University of Alberta in Edmonton, Canada; associate research scientist of molecular genetics at the Boyce Thompson Institute and adjunct professor at Cornell University in Ithaca, New York; and Gosney fellow at the California Institute of Technology in Pasadena, California. He has published over 160 scientific papers and holds over 50 issued patents and patent applications. Dr. Szalay is the recipient of the Wilhelm Exner Award (Medal for Excellence in Science) from Austria and the Alexander von Humboldt Prize from Germany, among others. He has functioned as an advisor for numerous research foundations, served on the Board of Directors and the Scientific Advisory Board for several biomedical start-up companies and was invited to serve as a genetic engineering, gene transfer and therapy expert for several multi-national pharmaceutical and diagnostic equipment manufacturing companies in the US, Europe and Japan.
Dr. Kevin T. Murphy joined Genelux Corporation in 2008. Dr. Murphy is a Board-Certified Radiation Oncologist on faculty at the University of California San Diego in the Department of Radiation Oncology in the Rebecca and John Moores NCI-designated Comprehensive Cancer Center. After spending time in private practice, he was recruited to UCSD in 2005, initially serving as Medical Director in the Department of Radiation Oncology and more recently as Director of Strategy and Business Development and Chief of the Stereotactic Radiosurgery and Pediatric Oncology Programs. His clinical and research interests focus on novel radiation technologies and their application in the treatment of children and tumors of the central nervous system. A graduate of the University of Notre Dame, Dr. Murphy received his M.D. and residency training at the University of Chicago. During his final year in Chicago, his research focused on the integration of radiation therapy and viral gene therapy in the treatment of cancer. Dr. Murphy will divide his time between Genelux Corporation and UCSD.
 Dr. Albert Röder joined Genelux Corporation in 2004 after retiring from Roche Applied Science as Head of Global R&D and Marketing Support. In February of that year, he was elected to the Board of Directors of Genelux Corporation. His distinguished 33-year career in the pharmaceutical industry included several operative and leadership positions in research and development, manufacturing, marketing, strategy and business development within international cross-functional teams. Before joining Roche, he worked for Boehringer Mannheim Biochemical, where he rose to Head of Research in Enzymology/Proteinchemistry and Chemistry, then to Head of the Global Product Supply Unit. He holds a PhD in organic chemistry from the University of Tübingen in Germany.
 Dr. Thomas served as the company’s first Chief Financial Officer before leaving the post in 2004. He has been a member of the Board of Directors since August 2002. He is currently Dean of the School of Business and Management at La Sierra University in Riverside, California, where he teaches finance, economics and entrepreneurship, a position he has occupied since July 1988. Dr. Thomas holds MBA degrees in finance and marketing, an MA in political economy and a PhD in economics and politics. He has received numerous awards honoring his success as a passionate teacher who motivates students to seek and achieve excellence, among them the Freedom Foundation’s Leavey Award for Excellence in Private Enterprise Education (1998), the Zapara Award to Teaching Excellence (1996) and the Riverside Chambers of Commerce Hero Award for Community Leadership (1995).
Copyright © 2007 Genelux |
Disclaimer
|